Jacobs Levy Equity Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Jacobs Levy Equity Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23,530	Closed	-$220K	–	1108
2025 Q2	$220K	Buy	+23,530	New	+$259K	﹤0.01%	974
2022 Q2	–	Sell	-27,664	Closed	-$481K	–	1080
2022 Q1	$481K	Buy	+27,664	New	+$466K	﹤0.01%	869
2020 Q2	–	Sell	-81,248	Closed	-$891K	–	1143
2020 Q1	$891K	Sell	81,248 -20,704	-20%	-$194K	0.01%	654
2019 Q4	$895K	Buy	101,952 +22,208	+28%	+$163K	0.01%	707
2019 Q3	$596K	Buy	79,744 +47,712	+149%	+$435K	0.01%	695
2019 Q2	$298K	Buy	32,032 +15,832	+98%	+$115K	﹤0.01%	815
2019 Q1	$85K	Sell	16,200 -26,739	-62%	-$153K	﹤0.01%	937
2018 Q4	$191K	Sell	42,939 -20,976	-33%	-$115K	﹤0.01%	893
2018 Q3	$516K	Buy	63,915 +23,100	+57%	+$165K	0.01%	772
2018 Q2	$287K	Buy	+40,815	New	+$400K	﹤0.01%	894

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Jacobs Levy Equity Management's SNDX Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 23,530 shares — an estimated $220K sold.

Jacobs Levy Equity Management first reported a position in SNDX in Q2 2018 and held it in 10 quarters. The position peaked at $895K in Q4 2019. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

Jacobs Levy Equity Management reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 23,530 Syndax Pharmaceuticals shares in Q3 2025, an estimated $220K.
Jacobs Levy Equity Management first reported a position in Syndax Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Jacobs Levy Equity Management's Syndax Pharmaceuticals position peaked at $895K in Q4 2019.
227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.